IRCT20110423006257N3 IRCT 2021-04-03 Arak University of Medical Sciences Thalidomide effects in COVID-19 A clinical trial to evaluate the therapeutic effects of thalidomide in patients with COVID-19 infection 2021-04-09 anticipated 66 Complete https://irct.ir/trial/53279 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balanced block randomization is used as a randomization method. Patients are divided into two groups using the above method. Therefore, six four-part combinations of intervention groups A and B are as follows : AABB, ABAB, ABBA, BBAA, BABA, BAAB. Then we assign them from the number one to six and with the table of random numbers from the right side of the selected number, move in order and select each of the numbers 1 to 6 of the above combination that appears, and the people who agree to participate in Study, fall into study groups. The allocation concealment will also be maintained in this method and the order of the quadruple compounds will also be completely hidden, Blinding description: In this study, the patients are randomly assigned to different groups and physicians. The physicians, patients , nurses, primary investigators, and also researchers who collect clinical data and researchers who evaluate the treatment response will be blinded to the patient groups and treatment protocol. 3 Covid 19. Intervention 1: Intervention group: In this group, in addition to the standard drugs recommended in the protocol of the Ministry of Health and supportive measures for patients, thalidomide (Lipomed-Swiss), in a dose of 100 mg, will be administered orally for 14 days (every night). Intervention 2: Control group: In this group, standard and recommended drugs are prescribed for patients in the protocol of the Ministry of Health and supportive measures, and they receive placebo drug, both in color and shape with the main drug, for 14 days (every night). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information